|
1.4 BIOLOGIE - TECHNOS
|
|
|
|
2. ETIOLOGIE
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
5.2 PHARMA
|
|
|
Eagle and Mystic lead AstraZeneca’s cancer clear out [Fierce Pharma]
|
|
|
|
|
|
AstraZeneca’s cull of the early-phase programs eliminated several other explorations of the efficacy of Imfinzi and tremelimumab in combination with other drugs. With AstraZeneca dropping anti-OX40 antibody MEDI0562, it has also kicked trials assessing its effect on solid tumors when combined with Imfinzi and tremelimumab to the curb.
|
|
|
|
|
|
|
|
“MedImmune” brand to be retired as biologics integrate into AstraZeneca’s new R&D structure [MedImmune]
|
|
|
|
|
|
While the MedImmune name and logo will no longer be used, a proud legacy of scientific innovation remains, as does the entrepreneurial culture that MedImmune has stood for over its 30-year history. Today nearly half of the AstraZeneca pipeline is comprised of biologics, providing momentum for the company’s newly structured R&D units to continue to discover and develop life-changing treatments as a fully integrated organization.
|
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
5.5.3 ASCO (PROSTATE)
|
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
Racial Disparities In Cancer Incidence And Survival Rates Are Narrowing [NPR]
|
|
|
|
|
|
During the period from 2006 to 2015, overall death rates from cancer declined 2.6 percent per year among black men, compared to 1.6 percent per year among white men. Among women, for that same time period, death rates from cancer declined 1.5 percent per year among blacks compared to 1.3 percent per year among whites.
|
|
|
|
|
|
|
|
6.2 IMPLANTS MAMMAIRES
|
|
|
|
6.7.2 APPLIS
|
|
|